StemCell Therapy

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

Story continues

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

View original content:http://www.prnewswire.com/news-releases/visiongain-report-global-rheumatoid-arthritis-drugs-market-estimated-to-grow-at-a-cagr-of-0-6-in-the-second-half-of-the-forecast-period-301022961.html

SOURCE Visiongain

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - Yahoo...

This entry was posted on March 21, 2020 at 9:44 pm and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |